From: The clinicopathological significance of neurogenesis in breast cancer
PGP 9.5 expression | ||||
---|---|---|---|---|
No. case | Negative | Positive | P-value | |
Tumor size | P = 0.319 | |||
≤ 2 cm | 86 | 30 (34.9%) | 56 (65.1%) | |
> 2 cm | 58 | 25 (43.1%) | 33 (56.9%) | |
Tumor grade | P < 0.0001 | |||
I | 34 | 24 (70.6%) | 10 (29.4%) | |
II - III | 110 | 31 (28.2%) | 79 (71.8%) | |
Tumor stage | P = 0.834 | |||
I | 23 | 10 (43.5%) | 13 (56.5%) | |
II | 74 | 27 (36.5%) | 47 (63.5%) | |
III | 47 | 18 (38.2%) | 29 (61.8%) | |
LN metastasis | P = 0.825 | |||
Negative | 75 | 28 (37.3%) | 47 (62.7%) | |
Positive | 69 | 27 (39.1%) | 42 (60.9%) | |
ER | P = 0.399 | |||
Negative | 80 | 33 (41.3%) | 47 (58.8%) | |
Positive | 64 | 22 (34.4%) | 42 (65.6%) | |
PR | P = 0.801 | |||
Negative | 70 | 26 (37.1%) | 44 (62.9%) | |
Positive | 74 | 29 (39.2%) | 45 (60.8%) | |
Disease free survival | P = 0.035 | |||
< 3 years | 54 | 19 (22.2%) | 35 (64.8%) | |
≥ 3 years | 90 | 48 (53.3%) | 42 (46.7%) |